Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 0168-583X
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Physics
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Psychopharmacology 111 (1993), S. 27-32 
    ISSN: 1432-2072
    Keywords: Pharmacokinetic ; Pharmacodynamic ; Interaction ; Remoxipride ; Biperiden
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Twelve healthy male volunteers took part in a double-blind randomised cross-over study composed of three treatment sessions: remoxipride 100 mg; remoxipride 100 mg plus biperiden 4 mg; and biperiden 4 mg. Plasma and urine concentrations of remoxipride and biperiden, plasma prolactin levels, salivary flow and adverse events were recorded to assess pharmacodynamic interactions. Remoxipride and biperiden had no effect on each other's plasma concentrations. Biperiden did not affect the urinary recovery or renal clearance of remoxipride. Prolactin levels were unaffected by biperiden but increased following remoxipride administration. Differences in prolactin Cmax and tmax following remoxipride versus concomitant (remoxipride + biperiden) treatment were not statistically significant. However, a slight but statistically significant (P=0.04) increase in prolactin AUC was observed after concomitant treatment. No significant differences could be observed between the recorded salivary flow in all the treatment sessions. Single doses of remoxipride and biperiden showed no pharmacokinetic or pharmacodynamic interaction.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1435-1463
    Keywords: Hypothermia ; DA D2 receptors ; FLA 797(−) ; FLA 908(−) ; NCQ 436(−) ; remoxipride
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Remoxipride and its active metabolites, the phenolic compounds FLA 797(−) and FLA 908(−) and the catecholic NCQ 436(−) and haloperidol, were examined for their ability to block hypothermia in the rat induced by dopamine (DA) D2 receptor stimulation. In addition, plasma levels of remoxipride and its active metabolites were measured using HPLC methods. Remoxipride (1 μmol/kg), given 30 or 15 min prior to, or 5 and 15 min after, the DA agonists, blocked the hypothermia induced by the DA D2 receptor agonists quinpirole (0.25mg/kg s.c.) and pergolide (0.1 mg/kg s.c). Administration of remoxipride by the i.v. or s.c. routes was more effective than by the i.p. route. FLA 797(−), FLA 908(−), and haloperidol were more effective than remoxipride in preventing the hypothermia caused by quinpirole, while NCQ 436(−) was less effective than remoxipride. The variation in time of remoxipride's action and effectiveness in blocking the induced hypothermia followed the variations in plasma concentrations. The plasma concentrations of the active metabolites were below the limit of determination (〈2 nmol/l). Based on estimation of free brain concentrations at effective dose levels together with in vitro affinities for the DA D2 receptor it was concluded that the metabolites FLA 797(−), FLA 908(−), and NCQ 436(−) do not appear to contribute to the antagonism of DA D2 mediated neurotransmission following a low remoxipride dose (1 μmol/kg).
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1435-1463
    Keywords: Bar test ; catalepsy ; remoxipride ; phenolic metabolites ; haloperidol ; plasma ; brain ; kinetics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The cataleptic effect of remoxipride was examined in the horizontal bar test after i.v.,i.p. and s.c. administration to male rats. Remoxipride induced immediate catalepsy after high i.v. doses (ED50=49 μmol/kg) while peak effects were seen 60–90 min after i.p. administration (ED50=38 μmol/kg). Following s.c. administration remoxipride failed to produce a statistically significant catalepsy in the 20–100 μmol/kg dose range (ED50 〉 100 μmol/kg). In contrast, haloperidol was found to be more effective in inducing catalepsy after i.v. (ED50=0.4 μmol/kg) than after i.p. or s.c. administration (ED50=0.9 μmol/ kg). The atypical antipsychotic profile of remoxipride was more pronounced when the compound was given i.v. or s.c. as compared with the i.p. route. Plasma and brain (striatum and nucleus accumbens) concentrations of remoxipride and its active phenolic metabolites FLA 797(−) and FLA 908(−) were measured by high performance liquid chromatography. The 40 μmol/kg dose of remoxipride resulted in plasma and brain concentrations of remoxipride which were 300–1000-fold higher (depending on the route of administration) than the most potent of the phenolic metabolites, e.g., FLA 797(−). The plasma and brain concentrations of remoxipride and its phenolic metabolites were related to DA D2 receptor blocking potency and to the temporal course and effectiveness to induce catalepsy. This analysis suggested that the unbound concentrations of the phenolic metabolites were too low to play a major role in the DA blocking action of remoxipride. However, FLA 797(−) may contribute marginally to the cataleptic effects following high (i.p.) doses of remoxipride.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1612-1112
    Keywords: Column liquid chromatography ; Ion-pair chromatography ; Peak compression ; Remoxipride metabolite ; Conjugate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Summary FLA 908 was identified as a metabolite of remoxipride in human urine after enzymatic hydrolysis. The identity was proven by comparison of its retention time in LC and its UV and mass spectra to authentic FLA 908. The concentration of FLA 908 in human urine was determined using chromatographic conditions where a peak compression effect was obtained. This effect, giving an extremely narrow peak for FLA 908, made it possible to determine low concentrations of the compound in enzymatically hydrolyzed urine. The limit of quantitation was improved more than by a factor of 5 compared to conventional chromatography and the precision was good with a coefficient of variation of 〈5%. Less than 1% (0.44–0.91%) of the administered remoxipride dose was found to be excreted as conjugated FLA 908 while only trace amounts (≤0.01%) of nonconjugated FLA 908 were seen.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...